Sumatriptan Injection, Solution
Product Images NDC 64380-740

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Sumatriptan (NDC 64380-740). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Strides Pharma Science Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sumatriptan-structure (7b0603f0 Ed39 460b 9d7b F19b95006024 01)

Chemical structure of sumatriptan, the active ingredient in SUMATRIPTAN injection, solution 6 mg/0.5 mL by Strides Pharma Science Limited. The diagram shows the molecular arrangement including various functional groups and bonds characteristic of sumatriptan.*

FDA Label Image

Device Image (7b0603f0 Ed39 460b 9d7b F19b95006024 02)

SUMATRIPTAN 6 mg/0.5 mL subcutaneous injection solution in a prefilled autoinjector pen. The device is white with a clear section to view the solution and has a blue cap. Labeler is Strides Pharma Science Limited. The product is intended for human prescription use.*

FDA Label Image

Image Description (7b0603f0 Ed39 460b 9d7b F19b95006024 03)

Illustration of a sumatriptan subcutaneous injection autoinjector showing three labeled parts: a gray cap that must be removed for the autoinjector to work, a medicine window to check if the liquid is clear, and a blue injection button that must be pressed firmly to start the injection.*

FDA Label Image

Figure A (7b0603f0 Ed39 460b 9d7b F19b95006024 04)

An instructional diagram showing the subcutaneous injection sites for sumatriptan injection, solution 6 mg/0.5 mL. The upper image depicts the injection being administered into the thigh, and the lower image shows injection into the arm.*

FDA Label Image

Figure B (7b0603f0 Ed39 460b 9d7b F19b95006024 05)

Illustration labeled Figure B showing a subcutaneous injection device for SUMATRIPTAN 6 mg/0.5 mL before injection, highlighting the presence of clear liquid inside the syringe.*

FDA Label Image

Figure C (7b0603f0 Ed39 460b 9d7b F19b95006024 06)

Illustration labeled as Figure C showing a subcutaneous injection device after use. The image highlights the blue plunger rod filling the window within the device, indicating completion of the injection process.*

FDA Label Image

Figure D (7b0603f0 Ed39 460b 9d7b F19b95006024 07)

An instructional illustration labeled Figure D, demonstrating how to pull the cap straight off a sumatriptan injection pen or syringe. The image shows two hands holding the device, highlighting the removal of the cap from the injection pen tip.*

FDA Label Image

Figure E (7b0603f0 Ed39 460b 9d7b F19b95006024 08)

Illustration labeled Figure E showing a comparison of two subcutaneous injection pen needle connectors. The left connector, marked with a green check, has a rounded open design, while the right connector, marked with a red X, has a narrower split design.*

FDA Label Image

Figure F (7b0603f0 Ed39 460b 9d7b F19b95006024 09)

Instructional illustration showing a hand holding a syringe for subcutaneous injection at a 90-degree angle to the skin. A callout instructs to press down against the skin to unlock the syringe before injection.*

FDA Label Image

Figure G (7b0603f0 Ed39 460b 9d7b F19b95006024 10)

Illustration showing the administration technique for sumatriptan subcutaneous injection. The image depicts a hand holding the prefilled syringe perpendicular to the skin, pressing down to inject, with an emphasis on the 'click' sound indicating correct pressure to release the medication.*

FDA Label Image

Figure H (7b0603f0 Ed39 460b 9d7b F19b95006024 11)

An instructional illustration labeled 'After Injection' showing a subcutaneous injection device held against the skin. The device's blue plunger is shown moving down, indicating it completely fills medicine flow after injection, demonstrating the final step in administering the dose.*

FDA Label Image

Figure I (7b0603f0 Ed39 460b 9d7b F19b95006024 12)

An instructional illustration showing the step of holding a SUMATRIPTAN injection pen against the skin with the instruction to wait 5 seconds before lifting the device after injection. The image demonstrates proper subcutaneous injection technique using the device.*

FDA Label Image

Figure J (7b0603f0 Ed39 460b 9d7b F19b95006024 13)

An instructional illustration showing a hand holding a sumatriptan autoinjector aimed at the skin, demonstrating the step of removing the autoinjector from the skin after administration.*

FDA Label Image

Figure K (7b0603f0 Ed39 460b 9d7b F19b95006024 14)

Illustration labeled Figure K showing a red biohazard disposal container with a rectangular opening at the top and a prominent warning label featuring the biohazard symbol.*

FDA Label Image

Autoinjector-label (7b0603f0 Ed39 460b 9d7b F19b95006024 15)

Label for Sumatriptan Injection USP 6 mg/0.5 mL autoinjector system for subcutaneous injection, single-dose. Manufactured by OneSource Specialty Pharma Limited and distributed by Strides Pharma Inc. Contains instructions and storage conditions, with NDC 64380-740-01 visible. Product of Spain.*

FDA Label Image

Autoinjector-carton (7b0603f0 Ed39 460b 9d7b F19b95006024 16)

The packaging label for Sumatriptan Injection USP 6 mg/0.5 mL autoinjector system for subcutaneous injection. The carton includes 2 autoinjectors, each containing a 0.5 mL prefilled syringe with 6 mg of sumatriptan. Labeler is Strides Pharma Inc. The label also provides step-by-step illustrated instructions for using the disposable autoinjector system.*

FDA Label Image

Time To Relief Of Cluster Headache From Time Of Injectiona (7b0603f0 Ed39 460b 9d7b F19b95006024 17)

A line graph showing estimated percentage of patients with relief over time (minutes) comparing Sumatriptan injection versus placebo. The graph plots percentage of relief on the vertical axis against time up to 25 minutes on the horizontal axis, with Sumatriptan showing a higher percentage of patient relief over time compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.